European Investment Bank

EQS-News: Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement

Retrieved on:

Wednesday, April 10, 2024

EIB, Peripheral nervous system, Patient, CNS, Schizophrenia, XETRA, European Investment Bank, BofA Securities, Pharmaceutical industry

Under the amendment, repayment of tranches one to three (out of a total of five) of the financing agreement with due dates from June 2024 to April 2025 will be shifted substantially, with tranche one now scheduled for November 25, 2025, tranche two for April 2026 and tranche three for June 2026.

Key Points:

Under the amendment, repayment of tranches one to three (out of a total of five) of the financing agreement with due dates from June 2024 to April 2025 will be shifted substantially, with tranche one now scheduled for November 25, 2025, tranche two for April 2026 and tranche three for June 2026.
The due dates for tranches four and five will stay unchanged.
On the amended tranches, Newron will start paying the agreed interest rates.
Details of the 2018 loan agreement can be found in Newron’s 2022 Annual Report which is posted on its website.

EQS-News: Marinomed Biotech AG announces agreement with European Investment Bank (EIB) to defer repayments of the 2019 venture loan for 18 months

Retrieved on:

Wednesday, April 10, 2024

Procter & Gamble, EIB, EUR, CFO, Virology, European Investment Bank, BofA Securities, Credit

Under the amendment, repayment of tranche one with a nominal value of EUR 4 million will be shifted from October 2024 to April 2026.

Key Points:

Under the amendment, repayment of tranche one with a nominal value of EUR 4 million will be shifted from October 2024 to April 2026.
Tranche two, with a nominal value of EUR 5 million, will be shifted from December 2025 to June 2027.
The amendment contains further terms and conditions, including the extension of the existing royalty agreement for five years.
The lenders of the real estate financing also agreed to suspend their capital repayments alongside with the EIB.

Powerful Medical's AI Breakthrough Marks a New Dawn in Heart Attack Diagnostics with EIC Support Doubles Sensitivity in Identifying Acute Coronary Occlusion on 12-Lead ECG

Retrieved on:

Monday, March 18, 2024

European Innovation Council, Longevity, Medicine, Cardiology, Patient, Splenic infarction, MD, EIC, Accelerator, European Investment Bank, Heart, EIB, FDA, Health, Medical device

With a landmark advancement in medical diagnostics, Powerful Medical has distinguished itself within the competitive digital health landscape.

Key Points:

With a landmark advancement in medical diagnostics, Powerful Medical has distinguished itself within the competitive digital health landscape.
At the core of its mission, Powerful Medical introduces the PMcardio platform, a CE-certified medical device leveraging proprietary AI to analyze electrocardiograms (ECGs) with remarkable precision.
This platform is capable of diagnosing heart attacks — specifically, occlusion myocardial infarctions — significantly earlier and with double the sensitivity compared to the current standard of care.
- Robert Herman, MD, Chief Medical Officer
As Powerful Medical begins its Series A fundraising, the EIC Accelerator's grant and investment endorse the company's vision and technology.

Inventiva reports its 2023 full-year results

Retrieved on:

Wednesday, March 27, 2024

Frédéric Cren, Chairman, CEO and cofounder of Inventiva, stated: “Inventiva achieved several clinical and financial milestones in 2023.

Key Points:

Frédéric Cren, Chairman, CEO and cofounder of Inventiva, stated: “Inventiva achieved several clinical and financial milestones in 2023.
R&D expenses for the fiscal year ended December 31, 2023, amounted to (€110.0) million compared to (€60.5) million in 2022.
Net financial income was (€5.1) million for the fiscal year ended December 31, 2023, compared to €2.8 million in 2022.
Income tax amounted to (€0.6) million for the 2023 fiscal year, compared to €0 million for 2022.

OpGen Announces Acquisition of Preferred Stock by David Lazar

Retrieved on:

Monday, March 25, 2024

Common stock, BofA Securities, Doctor of Philosophy, European Investment Bank, EIB, Trustee, Corporate development, Curetis, Corporation

On March 25, 2024, Mr. Lazar paid $200,000 at the initial closing of the transactions in exchange for 200,000 shares of Series E Preferred Stock.

Key Points:

On March 25, 2024, Mr. Lazar paid $200,000 at the initial closing of the transactions in exchange for 200,000 shares of Series E Preferred Stock.
Each share of Series E Preferred Stock is convertible into 24 shares of the Company’s common stock (“Common Stock”).
The conversion of the Series E Preferred Stock into shares of common stock in excess of applicable statutory and regulatory thresholds, including national stock exchange rules, will be subject to receipt of stockholder approval for the issuance of such shares of Common Stock.
We believe the transaction also offers future opportunities for OpGen stockholders to participate in possible future strategic transactions under the leadership of David Lazar and the new members of the board.

GenSight Biologics Reports Full Year 2023 Consolidated Financial Results

Retrieved on:

Friday, March 22, 2024

From 2022 to 2023, the Company's research and development expenses remained stable, at €19.3 million in 2022 and €19.4 million in 2023.

Key Points:

From 2022 to 2023, the Company's research and development expenses remained stable, at €19.3 million in 2022 and €19.4 million in 2023.
The Company's general and administrative expenses also remained stable and amounted to €5.4 million in 2022 and 2023.
The weighted average number of shares outstanding increased from 46.3 million in 2022 to 48.3 million in 2023, thereby reducing the loss per share from (€0.54) in 2023 to (€0.60) in 2023.
GenSight Biologics will report its cash position as of March 31, 2024 on April 4 2024.

Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement

Retrieved on:

Friday, March 15, 2024

Under the amendment, repayment of tranches one to three (out of a total of five) of the financing agreement with due dates from June 2024 to April 2025 will be shifted substantially, with tranche one now scheduled for November 25, 2025, tranche two for April 2026 and tranche three for June 2026.

Key Points:

Under the amendment, repayment of tranches one to three (out of a total of five) of the financing agreement with due dates from June 2024 to April 2025 will be shifted substantially, with tranche one now scheduled for November 25, 2025, tranche two for April 2026 and tranche three for June 2026.
The due dates for tranches four and five will stay unchanged.
On the amended tranches, Newron will start paying the agreed interest rates.
Details of the 2018 loan agreement can be found in Newron’s 2022 Annual Report which is posted on its website.

Link11 European Cyber Report 2023: DDoS Attacks Surge by 70%

Retrieved on:

Wednesday, March 13, 2024

BofA Securities, Microsoft, Denial-of-service attack, API, Growth, Apple, Prevalence, European Investment Bank, Arms industry

FRANKFURT, Germany, March 13, 2024 /PRNewswire/ -- The Link11 European Cyber Report 2023 highlights a dramatic 70% increase in DDoS attacks, with attacks reaching critical levels in just 14 seconds on average, compared to 55 seconds in 2022.

Key Points:

FRANKFURT, Germany, March 13, 2024 /PRNewswire/ -- The Link11 European Cyber Report 2023 highlights a dramatic 70% increase in DDoS attacks, with attacks reaching critical levels in just 14 seconds on average, compared to 55 seconds in 2022.
The report emphasizes the rising complexity of the threat landscape and the critical role of AI-based and automated security solutions in bolstering cyber resilience.
Politically motivated attacks significantly contributed to the surge, targeting prominent entities worldwide, including German federal states, the European Investment Bank, and Microsoft.
Geopolitical tensions globally contributed to a rapid escalation in DDoS attacks, particularly targeting critical infrastructure, public institutions, and political organizations.

Link11 European Cyber Report 2023: DDoS Attacks Surge by 70%

Retrieved on:

Wednesday, March 13, 2024

BofA Securities, Microsoft, Denial-of-service attack, API, Growth, Apple, Prevalence, European Investment Bank, Arms industry

FRANKFURT, Germany, March 13, 2024 /PRNewswire/ -- The Link11 European Cyber Report 2023 highlights a dramatic 70% increase in DDoS attacks, with attacks reaching critical levels in just 14 seconds on average, compared to 55 seconds in 2022.

Key Points:

FRANKFURT, Germany, March 13, 2024 /PRNewswire/ -- The Link11 European Cyber Report 2023 highlights a dramatic 70% increase in DDoS attacks, with attacks reaching critical levels in just 14 seconds on average, compared to 55 seconds in 2022.
The report emphasizes the rising complexity of the threat landscape and the critical role of AI-based and automated security solutions in bolstering cyber resilience.
Politically motivated attacks significantly contributed to the surge, targeting prominent entities worldwide, including German federal states, the European Investment Bank, and Microsoft.
Geopolitical tensions globally contributed to a rapid escalation in DDoS attacks, particularly targeting critical infrastructure, public institutions, and political organizations.

Euro Manganese Advances to Next Stage of Debt Funding Process with the European Investment Bank

Retrieved on:

Sunday, March 10, 2024

Reconstruction, Soil, Collection, European Commission, EIB, European Central Bank, European Investment Bank, Project, BofA Securities, MSP, EMN, Intergovernmentalism, ESG, Manganese, ASX, Private sector, Chvaletice

VANCOUVER, British Columbia, March 10, 2024 (GLOBE NEWSWIRE) -- Euro Manganese Inc. (TSX-V and ASX: EMN; OTCQX: EUMNF; Frankfurt: E06) (the "Company") today announced that its Chvaletice Manganese Project ("Chvaletice" or the "Project") is formally listed1 as under appraisal for debt financing with the European Investment Bank ("EIB").

Key Points:

VANCOUVER, British Columbia, March 10, 2024 (GLOBE NEWSWIRE) -- Euro Manganese Inc. (TSX-V and ASX: EMN; OTCQX: EUMNF; Frankfurt: E06) (the "Company") today announced that its Chvaletice Manganese Project ("Chvaletice" or the "Project") is formally listed1 as under appraisal for debt financing with the European Investment Bank ("EIB").
Funding from the EIB would complement a broader funding package to support the development of the Company’s high-purity battery-grade manganese plant in the Czech Republic.
Chvaletice remains the only sizable proven and probable reserve of manganese in the European Union and through the Project, Euro Manganese will be uniquely positioned to provide a secure, traceable, and responsibly produced supply of high-purity manganese products to the European electric vehicle market.
With the European Bank of Reconstruction and Development (“EBRD”) already as a key shareholder, today’s announcement is another key step towards achieving project funding.